Santersus completes first clinical trial for sepsis and Covid-19 treatment
September 30, 2021
Menu
News
Recent news
Santersus AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NucleoCapture™ blood purification technology for the treatment of severe, treatment-refractory systemic lupus erythematosus (SLE). This marks the second Breakthrough Device Designation awarded to NucleoCapture™, following earlier recognition for the treatment of sepsis.
October 22, 2024
Santersus AG is proud to announce the successful publication of its latest research, “Restoring discarded porcine lungs by ex vivo removal of neutrophil extracellular traps”, in the prestigious Journal of Heart and Lung Transplantation. This innovative work offers a transformative solution to address the global shortage of viable lungs for transplantation, utilizing advanced ex vivo lung perfusion (EVLP) techniques to repair lungs previously deemed unusable.
September 13, 2025
Santersus AG congratulates its alliance partner OrganOx Ltd on the company’s acquisition by Terumo Corporation in a transaction valued at up to $1.5 billion — a major milestone in the evolution of global transplant technologies.
Santersus AG presented its groundbreaking NucleoCapture technology at the prestigious BRAIN Conference 2024 in London. The event brought together global experts to advance neurovascular research and discuss cutting-edge developments in brain health.
January 11, 2021
First patients is enrolled to First In-Human Clinical Trial of NucleoCapture®
December 2, 2021
Ethics Committees of two major clinics approved NucleoCapture to proceed with a clinical trial in Sepsic Patients
November 26, 2021
Santersus’ Shareholders Elect New Board Members
September 22, 2021
Santersus AG Confirms Attendance at BioTech Gate
September 1, 2021
Santersus Raises CHF 750 thousand in Family & Friends Round
1 2 3 >
All news
Santersus’ therapeutic technology helps to treat sepsis
March 17, 2021